To treat or not to treat?
Millions Of Decisions A Day. Let's Make Them Better.
MeMed BV™ - a pioneering test for distinguishing between bacterial and viral infections that relies on the most accurate detection system - the body's immune system. MeMed BV™ aims to support physicians in making better informed antibiotic treatment decisions and tackling antimicrobial resistance - one of the biggest healthcare challenges of our time.
The test: MeMed BV™
The pipeline: Where immune response meets machine learning
We are applying machine learning to the complex signaling of the world's most accurate diagnostic system, crafted by nature – the immune system. Our pipeline of pioneering tests addresses key clinical challenges in infectious diseases and inflammatory disorders.
The platform: MeMed Key™
MeMed Key™ is a first of its kind immunoassay platform, that opens the way to measuring multiple proteins with central lab performance at the point-of-need. Key™ will run the MeMed BV™ test within minutes.
The evidence: Data is king
Our technology and products have been developed and rigorously validated in large multinational clinical studies encompassing thousands of patients and published in high impact scientific and medical journals.
What's New
.jpg)
MeMed Co-Founder & CEO, Dr. Eran Eden presented a Lightning Talk at BARDA's Industry Day, highlighting MeMed’s technology which profiles the host-immune response at the point-of-need.
VIEW HERE
We're growing!
If you are a top tier professional and a team player we would be happy to hear from you. Check out our current open positions.